ISSN: 2381-8727

Jornal Internacional de Inflamação, Câncer e Terapia Integrativa

Acesso livre

Nosso grupo organiza mais de 3.000 Séries de conferências Eventos todos os anos nos EUA, Europa e outros países. Ásia com o apoio de mais 1.000 Sociedades e publica mais de 700 Acesso aberto Periódicos que contém mais de 50.000 personalidades eminentes, cientistas de renome como membros do conselho editorial.

Periódicos de acesso aberto ganhando mais leitores e citações
700 periódicos e 15 milhões de leitores Cada periódico está obtendo mais de 25.000 leitores


Malizumab Efficacy and Safety in Adult Patients with Wheat-Dependent Exercise-Induced Anaphylaxis: Reduction in Basophil Activation in Vitro and Allergic Reaction to Wheat

Yoko Chin

Background: Anaphylactic shock occurs frequently in patients with wheat-dependent exercise-inducedanaphylaxis (WDEIA), so avoidance of wheat products is advised. The purpose of this study was to assess the efficacyand safety of long-term omalizumab treatment in adult patients with WDEIA [1, 2].
Methods: Twenty adult patients with WDEIA were enrolled in this phase 2 multicenter single-arm trial (UMIN 000019250). All patients received 150-600 mg of omalizumab subcutaneously, and assessments (basophil activation and blood examination) were performed at regular intervals during the administration (0-48 weeks) and observation periods (48–68 weeks). The primary endpoint was the proportion of patients who achieved a basophil activation rate of less than 10% with fractionated wheat preparations, and the secondary endpoint was the proportion of patients who had no allergic reactions after consuming wheat products [3].
Results: During treatment with omalizumab, more than 80% of patients had a basophil activation rate of less than 10% against all fractionated wheat preparations, and 68.8% of patients who met the primary endpoint had no allergic reaction. During the observation period, the proportion of patients with basophil activation rates less than 10% gradually decreased, while the proportion of patients with positive allergic reactions increased gradually and reached a maximum of 46.7%. During the study, no severe adverse events were observed [4].
Conclusions: Long-term omalizumab treatment is safe and effective for adult patients with WDEIA, as measured by basophil activation rate with wheat allergens and allergic reactions after removing wheat restrictions. This, however, is insufficient to achieve desensitisation.